Related Experiment Videos
[Thrombolysis in acute myocardial infarct: prerequisites, current experiences and remaining problems]
Schweizerische Medizinische Wochenschrift
|August 16, 1986
Summary
Coronary thrombolysis can reopen arteries after myocardial infarction, but its routine use is cautioned until long-term benefits on left ventricular function and patient survival are definitively proven.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Left ventricular pump failure is a primary cause of mortality in acute myocardial infarction.
- Thrombolytic therapy aims to preserve myocardium and improve patient outcomes.
Purpose:
- To review the efficacy, advantages, complications, and problems of different thrombolytic agents and administration routes for acute myocardial infarction.
- To discuss open questions regarding reocclusion and post-lytic treatment.
Summary:
- Examines streptokinase, urokinase, recombinant tissue-type plasminogen activator (rtPA), and anisoylated plasminogen streptokinase activator complex (APSAC).
- Evaluates studies published up to June 1986 on coronary thrombolysis efficacy and administration.
- Highlights the need for proven long-term benefits before routine clinical application.
Impact:
- Demonstrates the feasibility of reopening coronary arteries in acute myocardial infarction.
- Identifies critical areas for future research, including long-term patient prognosis and treatment strategies.
- Suggests that thrombolysis should not be routinely administered until long-term benefits are established.